Inovio Pharmaceuticals (INO) Payables (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Payables of $24.9 million for Q1 2026, down 37.86% sequentially from $40.1 million in Q4 2025, and up 148.99% YoY from $10.0 million in Q1 2025.
Inovio Pharmaceuticals (INO) Payables (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Payables for 17 years, with the latest figure at $24.9 million in Q1 2026.
- Quarterly Payables rose 148.99% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (up 148.99% YoY) and the FY2025 annual result came in at $40.1 million, up 174.68% from the prior year.
- Payables declined to $24.9 million in Q1 2026 per INO's latest filing, from $40.1 million in the prior quarter.
- Over five years, Payables peaked at $105.0 million in Q2 2022 and troughed at $711720.0 in Q3 2023.
- A 5-year average of $24.9 million and a median of $14.6 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2025: Payables plunged 99.04% in 2023, then surged 2720.22% in 2025.
- Over 5 years, Payables stood at $1.2 million in 2022, then surged by 1526.28% to $19.8 million in 2023, then dropped by 26.41% to $14.6 million in 2024, then surged by 174.68% to $40.1 million in 2025, then tumbled by 37.86% to $24.9 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $24.9 million, $40.1 million, and $50.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 35.57 Mn |
| 10 | Inovio Pharmaceuticals | 95.49 Mn | 95.49 Mn | - | 36.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.68 Mn |
| Mar 31, 2026 | 24.93 Mn |
| Dec 31, 2025 | 40.12 Mn |
| Sep 30, 2025 | 50.76 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 10.01 Mn |
| Dec 31, 2024 | 14.61 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 19.85 Mn |
| Sep 30, 2023 | 711,720.00 |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 24.75 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 74.15 Mn |
| Jun 30, 2022 | 105.02 Mn |
| Mar 31, 2022 | 38.12 Mn |
| Dec 31, 2021 | 47.64 Mn |
| Sep 30, 2021 | 28.65 Mn |